Evidence map›Paper›PMID 34250189›Full record

ArticleOpen forum infectious diseases2021

Recurring Severe Injection-Related Infections in People Who Inject Drugs and the Need for Safe Injection Sites in Madrid, Spain.

Jorge Valencia, Jesús Troya, Jeffrey V Lazarus, Guillermo Cuevas, Alejandro Alvaro-Meca, Juan Torres, Carlos Gardeta, David Lozano, Santiago Moreno, Pablo Ryan

Open access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Jorge ValenciaHarm Reduction Unit "SMASD," Addictions and Mental Health Department, Madrid, Spain.ORCID https://orcid.org/0000-0002-0148-2422
Jesús TroyaInternal Medicine Service, University Hospital Infanta Leonor, Madrid, Spain.ORCID https://orcid.org/0000-0001-7323-114X
Jeffrey V LazarusBarcelona Institute for Global Health, Hospital Clínic, University of Barcelona, Barcelona,Spain.ORCID https://orcid.org/0000-0001-9618-2299
Guillermo CuevasInternal Medicine Service, University Hospital Infanta Leonor, Madrid, Spain.ORCID https://orcid.org/0000-0001-7875-6359
Alejandro Alvaro-MecaUnit of Preventive Medicine and Public Health, Rey Juan Carlos University, Madrid, Spain.ORCID https://orcid.org/0000-0003-1315-4386
Juan TorresInternal Medicine Service, University Hospital Infanta Leonor, Madrid, Spain.ORCID https://orcid.org/0000-0002-8860-6837
Carlos GardetaHarm Reduction Unit "SMASD," Addictions and Mental Health Department, Madrid, Spain.
David LozanoHarm Reduction Unit "SMASD," Addictions and Mental Health Department, Madrid, Spain.
Santiago MorenoDepartment of Infectious Diseases, Ramon y Cajal Hospital, IRYCIS, University of Alcalá de Henares, Madrid, Spain.ORCID https://orcid.org/0000-0002-2843-1094
Pablo RyanInternal Medicine Service, University Hospital Infanta Leonor, Madrid, Spain.ORCID https://orcid.org/0000-0002-4212-7419
Hospital Universitario Infanta Leonor · ESBarcelona Institute for Global Health · ESUniversidad Complutense de Madrid · ESUniversidad de Alcalá · ESUniversidad Rey Juan Carlos · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAn estimated 58 749 people with opioid use disorder engaged in opioid agonist therapy (OAT) in 1132 centers in Spain during 2017. We aimed to calculate the incidence of severe injection-related infections in people who inject drugs (PWID) engaged in OAT in harm reduction settings without a safe consumption space.

methodsA retrospective cohort study was performed in PWID engaged in OAT and in a mobile harm reduction unit to quantify admissions to a referral hospital for any severe injection-related infections between 1 January 2016 and 31 December 2019. A Cox proportional hazard regression analysis was used to assess factors associated with any severe injection-related infection.

resultsTwo hundred thirty-seven PWID who engaged in OAT were included in the study. After a median follow-up of 5.5 months (interquartile range [IQR], 1.3-22.7 months), a total of 104 episodes of severe injection-related infections occurred among 56 individuals, and admission due to a second event occurred in 35.7% of this same group. The incidence density of any type of severe injection-related infection was 26.8 (95% confidence interval [CI], 20.2-34.8) episodes per 100 person-years, and the incidence density of complicated skin and soft tissue infections that required hospital admission was 20.4 (95% CI, 15.0-27.3) episodes per 100 person-years. Fifty-six (53.8%) of all the episodes were patient-directed discharge (PDD), and people who had 2 or more hospital admissions had a higher PDD frequency.

conclusionsSevere injection-related infections remain highly prevalent among PWID cared for in a harm reduction setting without a safe consumption space. PDD was more frequent among higher-risk individuals who presented 2 or more hospital readmissions.

Indexed as

harm reductionopioid agonist therapysafe injection sitessevere injection-related infectionsskin and soft tissue infections

Identifiers

PMID34250189
PMCPMC8266667
OpenAlexW3153251735

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.